Clinical Trial Update: HSCT for High Risk Inherited Inborn Errors [Phase 2]

View source ↗

Summary

A Phase 2 study updating hematopoietic stem cell transplantation for high-risk inherited metabolic disorders shows completed status with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenoleukodystrophy
• Metachromatic Leukodystrophy

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Adrenoleukodystrophy, Metachromatic Leukodystrophy | Phase 2 | Status: COMPLETED | Results posted: 2019-07-11